Fen-Dong Pharmaceuticals (300158.SZ) plans to invest 30 million yuan to establish a fund for investment in the field of biopharmaceuticals.

The ZhenDong Pharmaceutical (300158.SZ) announced that, in order to meet strategic development needs and fully leverage the power and resource advantages of professional investment institutions, integrate resources from multiple parties to obtain long-term investment returns, enhance overall competitiveness, without affecting the company's daily operations and development, effectively control investment risks, the company recently signed the "Wenzhou Longmen Huixin No. 3 Entrepreneurship Investment Partnership (Limited Partnership) Agreement" with Hainan Longmen Private Equity Fund Management Partnership Enterprise (Limited Partnership), Wen Nuo Yao, Beijing Xin Yi Consulting Co., Ltd., and Shanghai Weino Run Cheng Pharmaceutical Technology Co., Ltd. According to the partnership agreement, the company, as a limited partner, will subscribe for a capital contribution of 30 million yuan in self-owned funds, with a contribution ratio of 28.5687%, and bear limited liability based on the amount of subscribed capital, mainly investing in the field of biomedicine.